AbCellera Biologics(DE:8QQ)
€10.88+0.28 (+11.13%)
DE:8QQ
AbCellera Biologics stock forecast
€10.88
At close:+0.28 (+11.13%)
AbCellera Biologics (8QQ) Stock Forecast & Price Target
7 Followers
8QQ Analyst Ratings
Strong Buy
8Buy1Hold0Sell
Based on 9 analysts giving stock ratings to AbCellera Biologics in the past 3 months
8QQ Stock 12 Month Forecast
Average Price Target
€17.23▲(58.33% Upside)Based on 9 Wall Street analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is EUR 17.23 with a high forecast of EUR 26.73 and a low forecast of EUR 12.47. The average price target represents a 58.33% change from the last price of EUR 10.88.
Past 12 Months12 Month ForecastJan2026Oct2026
High€26.73
Average€17.23
Low€12.47
Highest Price TargetHighest€26.73Average Price Target€17.23Lowest Price TargetLowest€12.47
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Stephen Willey | Stifel Nicolaus | €8.02→€12.47 | buy | 14.66%Upside | Assigned | 11/10/26 | ||
| Evan Seigerman | BMO Capital | €13.37 | buy | 22.85%Upside | Reiterated | 11/10/26 | ||
| Brian Cheng | J.P. Morgan | €15.15 | buy | 39.23%Upside | Reiterated | 11/10/26 | ||
| Debanjana Chatterjee | JonesTrading | €22.28 | buy | 104.74%Upside | Reiterated | 11/10/26 | ||
| Steven Seedhouse | Cantor Fitzgerald | €17.82 | buy | 63.79%Upside | Reiterated | 11/09/26 | ||
| Andrea Newkirk | Goldman Sachs | €11.58→€12.47 | hold | 14.66%Upside | Reiterated | 11/09/26 | ||
| Roger Song | Jefferies | €18.71 | buy | 71.98%Upside | Initiated | 10/30/26 | ||
 Unknown AnalystNot Ranked | UBS | €16.04 | buy | 47.41%Upside | Initiated | 10/11/26 | ||
| Srikripa Devarakonda | Truist Financial | €26.73 | buy | 145.69%Upside | Reiterated | 09/02/26 | ||
| Allison Bratzel | Piper Sandler | €10.69 | buy | -1.72%Downside | Reiterated | 08/07/26 | ||
| Brendan Smith | TD Cowen | ― | buy | ― | Reiterated | 08/05/26 | ||
| David Martin PhD | Bloom Burton | €8.02 | buy | -26.29%Downside | Reiterated | 11/19/25 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Stephen WilleyStifel Nicolaus | BuyAssigned€8.02→€12.47 | 11/10/26 | 14.66%Upside | ||
| Evan SeigermanBMO Capital | BuyReiterated€13.37 | 11/10/26 | 22.85%Upside | ||
| Brian ChengJ.P. Morgan | BuyReiterated€15.15 | 11/10/26 | 39.23%Upside | ||
| Debanjana ChatterjeeJonesTrading | BuyReiterated€22.28 | 11/10/26 | 104.74%Upside | ||
| Steven SeedhouseCantor Fitzgerald | BuyReiterated€17.82 | 11/09/26 | 63.79%Upside | ||
| Andrea NewkirkGoldman Sachs | HoldReiterated€11.58→€12.47 | 11/09/26 | 14.66%Upside | ||
| Roger SongJefferies | BuyInitiated€18.71 | 10/30/26 | 71.98%Upside | ||
| Unknown AnalystUBSNot Ranked | BuyInitiated€16.04 | 10/11/26 | 47.41%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiterated€26.73 | 09/02/26 | 145.69%Upside | ||
| Allison BratzelPiper Sandler | BuyReiterated€10.69 | 08/07/26 | -1.72%Downside | ||
| Brendan SmithTD Cowen | BuyReiterated | 08/05/26 | ― | ||
| David Martin PhDBloom Burton | BuyReiterated€8.02 | 11/19/25 | -26.29%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering AbCellera Biologics
3 Months
Success Rate7/12 ratings generated profit
58%
Average Return
+33.03%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +33.03% per trade.
1 Year
Success Rate11/11 ratings generated profit
100%
Average Return
+121.32%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +121.32% per trade.
2 Years
Success Rate11/11 ratings generated profit
100%
Average Return
+236.64%
Copying Brendan Smith's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +236.64% per trade.
8QQ Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 8 | 5 |
| Buy | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 14 | 16 | 14 | 12 |
In the current month, 8QQ has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 8QQ average Analyst price target in the past 3 months is 17.23.
8QQ Financial Forecast
High€-0.12
Consensus€-0.15
Low€-0.18
8QQ Earnings Forecast
Next quarter’s earnings estimate for 8QQ is -EUR 0.15 with a range of -EUR 0.18 to -EUR 0.12. The previous quarter’s EPS was -EUR 0.12. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€14.1M
Consensus€6.4M
Low€3.09M
8QQ Sales Forecast
Next quarter’s sales forecast for 8QQ is EUR 6.40M with a range of EUR 3.09M to EUR 14.06M. The previous quarter’s sales results were EUR 9.59M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
8QQ Stock Forecast FAQ
What is DE:8QQ’s average 12-month price target, according to analysts?
Based on analyst ratings, AbCellera Biologics’s 12-month average price target is €17.23.
What is DE:8QQ’s upside potential, based on the analysts’ average price target?
AbCellera Biologics has 58.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AbCellera Biologics a Buy, Sell or Hold?
AbCellera Biologics has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is AbCellera Biologics’s share price target?
The average share price target for AbCellera Biologics is €17.23. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €26.73, and the lowest forecast is €12.47. The average share price target represents a 58.33% increase from the current price of €10.88.
What do analysts say about AbCellera Biologics?
AbCellera Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of AbCellera Biologics?
To buy shares of DE:8QQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
